Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CMS Medical Venture Investment
Hong Kong, China
- Ownership
- Private
- Development stage
- Other
01
Overview
CMS Medical Venture Investment is the Hong Kong–based corporate venture arm of China Medical System that makes minority equity investments in early-stage biotech and life science companies, often alongside regional development and commercialization agreements led by its parent company.
- Industry
- Investors
02
Partnerships
Acticor Biotech – equity investment via Series B financing, alongside a regional development and commercialization collaboration between Acticor Biotech and China Medical System/CMS Medical LimitedCan-Fite BioPharma – received payments under a regional licensing agreement in which CMS Medical Venture Investment Limited is a party to the investment componentCambridge Judge Business School and AstraZeneca – indirect collaboration through China Medical System’s UK early‑stage biotech investment initiative with a Cambridge focus
Beyond the preview
Go deeper on CMS Medical Venture Investment.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CMS Medical Venture Investment.